BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Wednesday, April 24, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» SGLT2 inhibition ameliorates endothelial dysfunction tied to ALDH2*2 variant
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Cardiovascular
SGLT2 inhibition ameliorates endothelial dysfunction tied to ALDH2*2 variant
Jan. 30, 2023
No Comments
About 8% of the worldwide population carries the aldehyde dehydrogenase 2 (ALDH2) alcohol flushing variant (
ALDH2*2
, rs671), which has been tied to an increased risk of coronary artery disease (CAD) due to severe loss of ALDH2 enzymatic activity.
BioWorld Science
Cardiovascular